#41631

IN THE UNITED STATES PATENT AND TRADEMARK PECEIVED

In re Application of

Emil Israel KATZ

MAR 0 4 2002

Serial No.

09/982,172

TECH CENTER 1600/2900

Filed For:

FEB 2 8 2002 WILL

October 19, 2001

PEPTIDES REPRESENTATIVE OF

POLYPEPTIDES OF INTEREST ...

Attorney Docket

01/22283

Art Unit

Commissioner of Patents and Trademarks Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Sol Sheinbein

Attorney for Applicant Registration No. 25,457

February 26, 2002

Please type a plus sign (+) inside this box -

PTO/SB/08A (10-96) Approved for use through 10/31/99 OMB 0651-0031 atent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Pape	erwork Re	duction Act	of 1995, no	persons	are required	spond to a col	lection of information un	nless it contains a valid OMB contr		
		Substitu	ute for form	Application Number	if Known					
	•	NIEGE	3 TA A 1TC	Filing Date	09/982,172 October 19, 20					
			RMAT	First Named Inventor						
	5	STATI	EMEN	Group Art Unit	KATZ et al					
		(us	e as many	Examiner Name						
Chast		(45)		- 57100	of		· · · · · · · · · · · · · · · · · · ·			
Sheet		1				C DATENIE	DOCUMENTO	Attorney Docket Number	01/22283	
	ı	II S Pat	ent Docum	ent	U.S. PATENT DOCUMENTS					
Examiners Initials	Cite No. ¹	Number Kind Code ² (if known)			Name of Patentee or Applicant of Cited Document			Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, li Where Relevar Passages or Relev Figures Appea	
	AA	6,261,569			Comis	et al		07-17-2001		
	AB	5,872,234			Bandman et al			02-16-1999		
				ļ						
						.				
				<u> </u>			· · · · · · · · · · · · · · · · · · ·			
							<u></u> .			
	-			ļ						
				-					 	
					-		···			
	· 1	For	nian Datant	Dogum		EIGN PATE	NT DOCUMEN	TS		
Examiners Initials	Cite No. 1				nd Code ⁵ known)	Name of Patentee or Applicant of Cited Document		Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	
								+		
Examiner Signature								Date Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 2023 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this by TRADENA

PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE

Under the Paperwork Reduction Act of 1995, no per juired to respond to a collection of information unless it contains a valid OMB control number.

Onder the Paper	VOIR REGULETIO	il Act of 1993, no persons are te	quired to respond to a d	conection of information un	less it com						
	Su	bstitute for form 1449A/PTO	Complete if Known Application Number 09/982								
	INE	ORMATION DI	Filing Date		09/982,172 October 19, 200						
				First Named Inventor		KATZ et al					
	SIA	ATEMENT BY A	L	Group Art Unit		KAIZetai					
		(use as many sheets as	nacassami)			ner Name		<u> </u>			
						ļ					
Sheet		2 of		I D A TED ITT I I I I I I I I I I I I I I I I I			01/22	01/22283			
From in an	- C:4-	UTHER PRIC	OR ART - NON	PATENT LITERA	ATURE	DOCUMENTS	- 64				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.									
	BA	Marks et al, "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", <i>Bio/technology</i> , 10:779-783, 1992									
	BB	Söderlind et al, "Complementary-Determining Region (CDR) Implantation: A Theme of Recombination", <i>Immunotechnology</i> , 4:279-285, 1999									
	BC	Söderlind et al, "Recombining Germline-Derived CDR Sequences for Creating Diverse Single-Framework Antibody Libraries", <i>Nature Biotechnology</i> , 18:852-856, 2000									
	BD	Ohlin et al, Light Chain Shuffling of a High Affinity Antibody Results in a Drift in Epitope Recognition", <i>Molecular Immunology</i> , 33(1):47-56, 1996									
	BE	Hemminki et al, "Fine Tuning of an Anti-Testosterone Antibody Binding Site by Stepwise Optimisation of the CDRs", <i>Immunotechnology</i> , 4:59-69, 1998									
	BF	Barbas III et al, "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site", Proc. Natl. Acad. Sci. USA, 88:7978-7982, 1991									
	BG	Hoogenboom et al, "Antibody Phage Display Technology and its Applications", Molecular Immunology, 4:1-20, 1998									
	ВН	Haupt et al, "Plastic Antibodies: Developments and Applications", <i>Trends Biotech.</i> , 16:468-476, 1998									
	BI	Vlatakis et al, "Drug Assay Using Antibody Mimics Made by Molecular Imprinting", <i>Nature</i> , 361:645647, 1993									
	BJ	Arnon, R., "Synthetic Peptides as the Basis for Vaccine Design", Molecular Immunology, no further info given									
	BK	Arnheiter et al, "Physicochemical and Antigenic Properties of Synthetic Fragments of Human Leukocyte Interferon" <i>Nature</i> , 294:278-280, 1981									
	BL	Mariani et al, "Immunogenicity of a Free Synthetic Peptide: Carrier Conjugation Enhances Antibody Affinity for the Native Protein", <i>Molecular Immunology</i> , 24(3):297-303, 1987									
	ВМ	Chames et al, "Antibody Engineering and its Applications in Tumor Targeting and Intracellular Immunization", FEMS Microbiology Letters, 189:1-8, 2000									
	BN .	Hoogenboom et al, "Natural and Designer Binding Sites Made by Phage Display Technology", <i>Immunology Today</i> , 21(8):371-378, 2000									
	ВО	Nelson et al, "Demystified Monoclonal Antibodies", <i>J. Clin. Pathol.: Mol Pathol.</i> , 53:111-117, 2000									
	BP	Li, Min, "Applications of Display Technology in Protein Analysis", Nature Biotechnology, 18:1251-1256, 2000									
	BQ	Borrebaeck, Carl A.K., "Antibodies in Diagnostics-From Immunoassays to Protein Chips", Immunology Today, 21(8):379-381, 2000									
Examiner						Date					
Signature	1					Considered					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 2023 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.